|
India News Releases
|
(India.CityRegions.Com, December 17, 2016 ) Metachromatic leukodystrophy is an inherited disorder characterized by the accumulation of fats called sulfatides in cells. Symptoms include vision problems leading to blindness, personality changes, and motor disturbances such as clumsiness, muscle weakness (hypotonia), rigidity, inability to coordinate movement (ataxia), and/or muscle spasms especially of the neck, spine, arms, and legs. Treatment for metachromatic leukodystrophy is symptomatic and supportive.
Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide Metachromatic Leukodystrophy (MLD) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metachromatic Leukodystrophy (MLD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Metachromatic Leukodystrophy (MLD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.Metachromatic Leukodystrophy (MLD).
Metachromatic Leukodystrophy (MLD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Complete Report at http://www.reportsweb.com/metachromatic-leukodystrophy-mld-pipeline-review-h2-2016
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Metachromatic Leukodystrophy (MLD) Infertility - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metachromatic Leukodystrophy (MLD) Infertility and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metachromatic Leukodystrophy (MLD) Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metachromatic Leukodystrophy (MLD) Infertility pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001506607/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metachromatic Leukodystrophy (MLD) Infertility - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metachromatic Leukodystrophy (MLD) Infertility pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001506607/discount
List of Tables
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2016 7 Number of Products under Development for Metachromatic Leukodystrophy (MLD) - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Metachromatic Leukodystrophy (MLD) - Pipeline by ArmaGen Inc, H2 2016 15 Metachromatic Leukodystrophy (MLD) - Pipeline by GlaxoSmithKline Plc, H2 2016 16 Metachromatic Leukodystrophy (MLD) - Pipeline by Novartis AG, H2 2016 17 Metachromatic Leukodystrophy (MLD) - Pipeline by Nuo Therapeutics Inc, H2 2016 18
List of Figures
Number of Products under Development for Metachromatic Leukodystrophy (MLD), H2 2016 7 Number of Products under Development for Metachromatic Leukodystrophy (MLD) - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Targets, H2 2016 22 Number of Products by Mechanism of Actions, H2 2016 23 Number of Products by Stage and Mechanism of Actions, H2 2016 23 Number of Products by Routes of Administration, H2 2016 25 Number of Products by Stage and Top 10 Routes of Administration, H2 2016 25 Number of Products by Molecule Types, H2 2016 27
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|